{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028686","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2026-06-15T20:05:40+00:00","discovered_at":"2026-06-15T20:07:00.269149+00:00","generated_at":"2026-06-15T20:15:27.570888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"PURE Bioscience reports Q3 net loss of $624k; CEO Bartlett to retire July 31, Kitchell to succeed","bullets":["Q3 net product sales $506k (+3.5% YoY); net loss $624k vs $580k YoY; EPS ($0.01).","Nine-month net product sales $1.66M (+15.4% YoY); net loss $1.87M vs $2.07M YoY.","CEO Robert Bartlett retiring July 31, 2026; President Jeff Kitchell appointed CEO effective Aug 1.","Director Bernard Blotner leaving board due to health; no replacement named."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028686","json":"https://secwatch.observer/filing/0001493152-26-028686.json","markdown":"https://secwatch.observer/filing/0001493152-26-028686.md","text":"https://secwatch.observer/filing/0001493152-26-028686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:15:27.570888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34590c5708b65220ed23e44ad074788261cd73c7","claim":"PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2026 results: revenue $1,656,000, net income $1,873,000, EPS ($0.02).","evidence_excerpt":"per share was ($0.01) for the fiscal third quarters ended April 30, 2026 and 2025, respectively. Summary of Results of Operations – Prior Nine Months ● Net product sales were $1,656,000 and $1,435,000 for the nine months ended April 30, 2026 and 2025, respectively. The $221,000 increase was attributable to higher sales across our end-user network. ● Net loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended April 30, 2026"},{"label":"Revenue","value":"$1,656,000"},{"label":"Net income","value":"$1,873,000"},{"label":"EPS","value":"($0.02)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e9580b6042f3861da4cf74e7560581357a664735","claim":"PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2026 results: revenue $506,000, net income $624,000, EPS ($0.01).","evidence_excerpt":") antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2026. Summary of Results of Operations – Third Quarter ● Net product sales were $506,000 and $489,000 for the fiscal third quarters ended April 30, 2026 and 2025, respectively. The $17,000 increase was attributable to higher sales across our distribution network. ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended April 30, 2026"},{"label":"Revenue","value":"$506,000"},{"label":"Net income","value":"$624,000"},{"label":"EPS","value":"($0.01)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}